Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double‐blind, randomized, placebo‐controlled trial
…, JT Sharp, PA Ory, RJ Perdok… - … : Official Journal of …, 2005 - Wiley Online Library
… Ms Perdok and Dr. Weinberg own stock in Abbott. … Ms Perdok and Dr. Weinberg own
stock in Abbott. … Ms Perdok and Dr. Weinberg own stock in Abbott. …
stock in Abbott. … Ms Perdok and Dr. Weinberg own stock in Abbott. …
Adalimumab for long‐term treatment of psoriatic arthritis: forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial
…, JT Sharp, PA Ory, RJ Perdok… - … : Official Journal of …, 2007 - Wiley Online Library
Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human
anti–tumor necrosis factor (anti‐TNF) monoclonal antibody, over 48 weeks in patients with …
anti–tumor necrosis factor (anti‐TNF) monoclonal antibody, over 48 weeks in patients with …
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
…, C Birbara, GTD Thomson, RJ Perdok… - Annals of the …, 2009 - ard.bmj.com
Objective: To evaluate the long-term effectiveness and tolerability of adalimumab in the
treatment of psoriatic arthritis (PsA). Methods: Patients with PsA who completed a 24-week, …
treatment of psoriatic arthritis (PsA). Methods: Patients with PsA who completed a 24-week, …
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
…, GTD Thomson, AJ Kivitz, RJ Perdok… - The Journal of …, 2007 - jrheum.org
OBJECTIVE: To demonstrate the safety and efficacy of adalimumab for the treatment of
active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying …
active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying …
Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial
…, GM Shepherd, RA Rode, RJ Perdok… - Diabetes, Obesity …, 2012 - Wiley Online Library
Aim: The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced
greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality…
greater mean weight loss than placebo but increased cardiovascular morbidity but not mortality…
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab …
…, PJ Mease, MA Cifaldi, RJ Perdok… - Annals of the …, 2007 - ard.bmj.com
… RJ Perdok4, … Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of
life in patients with psoriatic arthritis. A comparison with patients with rheumatoid arthritis. …
life in patients with psoriatic arthritis. A comparison with patients with rheumatoid arthritis. …
[HTML][HTML] Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
…, PJ Mease, EHS Choy, CT Ritchlin, RJ Perdok… - Arthritis research & …, 2010 - Springer
Introduction To identify independent predictors of radiographic progression in psoriatic arthritis
(PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in …
(PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in …
Efficacy and safety of ABT-874, a monoclonal anti–interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60 …
…, KB Gordon, RG Langley, A Menter, RJ Perdok… - Journal of the American …, 2011 - Elsevier
BACKGROUND: ABT-874, an anti–interleukin-12 and -23 antibody, was previously shown
to be significantly more effective compared with placebo during a 12-week phase II study of …
to be significantly more effective compared with placebo during a 12-week phase II study of …
Cross-Study Review of the Clinical Efficacy of Apomorphine SL 2 and 3 mg:: Pooled Data from Three Placebo-Controlled, Fixed-Dose Crossover Studies
C Stief, RJ Padley, RJ Perdok, DJ Sleep - European Urology Supplements, 2002 - Elsevier
Background: Sublingual (SL) apomorphine is a nonopioid, centrally acting dopamine
agonist developed to treat erectile dysfunction (ED). Clinical trials of the drug, using the most …
agonist developed to treat erectile dysfunction (ED). Clinical trials of the drug, using the most …
Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and III studies
DJ Ralph, DJ Sleep, RJ Perdok, RJ Padley - European Urology …, 2002 - Elsevier
Background: In 1999, the World Health Organization (WHO) Consensus Panel recommended
orally administered drugs as first-line treatment of erectile dysfunction. Apomorphine SL, a …
orally administered drugs as first-line treatment of erectile dysfunction. Apomorphine SL, a …